| Document |
Document Title |
|
WO/2023/099072A1 |
Compounds of formula (I) wherein Y, n, R1, R2 and R3 have the meanings indicated herein, or a pharmaceutically acceptable solvate or salt thereof, are disclosed. The compounds are useful as inhibitors of protein or lipid kinases (in part...
|
|
WO/2023/100975A1 |
The present invention provides a pharmaceutical formulation that reduces formation of particles including an anti-IL-6 receptor antibody that inhibits binding with a receptor for interleukin 6 or an anti-blood coagulation factor IXa/X an...
|
|
WO/2023/098637A1 |
The present invention relates to a method for preventing and/or treating thromboembolic diseases, comprising the following step: administering a coagulation factor XI (FXI) binding protein to a subject in need thereof, which binding prot...
|
|
WO/2023/095162A1 |
The present invention provides Cocrystal of Roxadustat Nicotinamide Form II and Cocrystal of Roxadustat Nicotinamide Form III, processes for their preparation and pharmaceutical composition thereof.
|
|
WO/2023/095802A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2023/097119A2 |
The present invention provides methods of treating a disease or disorder in a subject comprising administering to the subject a therapeutically effective amount of an agent that modulates RIOK2.
|
|
WO/2023/097148A1 |
Disclosed herein are hemostatic materials and methods of production and use thereof.
|
|
WO/2023/088111A1 |
Provided herein is a potassium-binding polymer prepared by polymerization reaction of a monomer and a crosslinking agent, wherein the monomer is the compound of formula (V), the crosslinking agent is the compound of formula (VI), and/or ...
|
|
WO/2023/091783A1 |
Disclosed are methods of making engineered cells comprising reduced Sirt6 expression as well as the cells that are the products of said methods. Thus, in one aspect, disclosed herein are engineered lymphocytes comprising reduced Sirt6 ex...
|
|
WO/2023/092062A1 |
This disclosure relates to dosage regimens for anti-Factor XI and/or activated Factor XI (Factor XIa) antibodies or antigen-binding fragments thereof, pharmaceutical formulations comprising the same, and pharmaceutical formulations for u...
|
|
WO/2023/088415A1 |
An Andrias davidianus skin secretion hydrolysate, and a preparation method therefor and an application thereof The preparation method comprises: S1: mixing a disulfide bond reducing agent and a first solvent to obtain a second solvent; S...
|
|
WO/2023/091968A1 |
Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a sub...
|
|
WO/2023/088272A1 |
Provided are an underglycosylated kallikrein I (KLK1) subjected to no glycosylation or only a small amount of glycosylation at an NFS sequence, and a polyethylene glycol modifier thereof and the pharmaceutical use thereof. Compared with ...
|
|
WO/2023/091875A1 |
A bi-functional fusion protein that inhibits a complement signaling pathway is provided, the bi-functional fusion protein comprises a complement C4b binding motif, a complement C3b binding motif, and an Fc region. A method of treating or...
|
|
WO/2023/090411A1 |
Provided is a pharmaceutical composition for treating and/or preventing at least one among heart disease, heart disease complications, skeletal muscle disease, and skeletal muscle disease conditions, the pharmaceutical composition having...
|
|
WO/2023/091414A1 |
Provided herein is the use of certain pyruvate kinase activators or pharmaceutically acceptable salts or compositions thereof for treating MDS -associated anemia and other conditions.
|
|
WO/2023/089575A1 |
The present invention relates to an orodispersible pharmaceutical dosage form of edoxaban having overall improved characteristics, its process of manufacturing and its use as anticoagulant.
|
|
WO/2023/082397A1 |
Disclosed are an A-FABP protein inhibitor and a use thereof, relating to the technical field of metabolic diseases, and cardiovascular and cerebrovascular complications thereof. Disclosed is an A-FABP protein inhibitor, an active ingredi...
|
|
WO/2023/086390A1 |
The invention provides methods and compositions for providing myocardial protection and for treatment of myocardial stress and fibrosis, which include the administration of PZ-128.
|
|
WO/2023/086388A1 |
Various embodiments of the invention utilize chalcones to treat blood, bleeding, and/or bleeding disorders. As described herein, chalcones significantly reduce blood clotting time in normal/hemophilic blood and normal/hemophilic animal m...
|
|
WO/2023/083281A1 |
The present invention relates to a use of a quinolinone derivative in treatment of immune thrombocytopenia, and in particular to a use of a compound of formula (I) or a pharmaceutically-acceptable salt or pharmaceutical composition there...
|
|
WO/2023/083296A1 |
The present application provides the use of a PDE4 inhibitor (e.g., a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof) in the preparation of a drug for reducing uric acid levels and preventing uric acid lev...
|
|
WO/2023/079294A1 |
The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: whe...
|
|
WO/2023/077230A1 |
Provided herein are wildtype and mutant single chain variable fragments (scFvs) of the anti-PF4/heparin monoclonal antibody KKO, and variants thereof which are useful for distinguishing between platelet-activating (pathogenic) and non-ac...
|
|
WO/2023/081212A1 |
The invention relates to methods of treating functional iron deficiency (FID) associated with low, very low, or intermediate risk myelodysplastic syndromes, FID associated with primary myelofibrosis (PMF), post-polycythemia vera myelofib...
|
|
WO/2023/077225A1 |
The present disclosure is generally directed to a delivery device for the automatic injection of a dose of a fluid into the target site of a subject. The delivery device generally includes a lower body, an upper body that can be movably ...
|
|
WO/2023/077413A1 |
Provided are a protein containing an amino acid sequence capable of binding to a peptide fragment of a substrate GPRP, a fibrinogen-like protein 1 (FGL1) containing the amino acid sequence, and a fibrinogen domain (FD) of the FGL1, where...
|
|
WO/2023/080939A1 |
Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral scler...
|
|
WO/2023/081681A1 |
Disclosed herein are nitric oxide donors and methods of use thereof.
|
|
WO/2023/081804A1 |
Provided herein are materials and methods for the preparation of blood products. In some aspects, provided herein are compositions that include populations of platelet derivatives, including freeze-dried platelet derivatives, methods of ...
|
|
WO/2023/081801A2 |
Provided herein are methods of using voxelotor for the treatment of sickle cell disease in patients, wherein the patient is about 4 years old to less than about 12 years old. Provided herein are methods of using voxelotor for the treatme...
|
|
WO/2023/074459A1 |
The composition of the present invention contains, as active ingredients, the following ingredients (1) to (3). Ingredient (1): at least one crude drug selected from the group consisting of coix seed, Plantago asiatica seed, Plantago a...
|
|
WO/2023/071905A1 |
Provided are a tissue-specific promoter and use thereof. The tissue-specific promoter has a nucleic acid sequence comprising more than 80% of the sequence as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. The tissue-s...
|
|
WO/2023/072240A1 |
Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.
|
|
WO/2023/077053A2 |
Guide RNAs and CRISPR/Cas systems targeting a C5 locus or gene, lipid nanoparticles or viral vectors comprising such guide RNAs or CRISPR/Cas systems, and cells or animals comprising such guide RNAs or systems are provided. Methods of mo...
|
|
WO/2023/072311A1 |
Provided are a Whitmania pigra polypeptide against coagulation factor XIa and a mutant thereof. A Kunitz-type polypeptide sequence is screened from a salivary gland transcriptome database of Whitmania pigra and subjected to expression co...
|
|
WO/2023/074562A1 |
The purpose of the present invention is to provide a hollow fiber membrane that is capable of efficiently removing extracellular vesicles (vesicles) from a liquid, in particular blood, and a hollow fiber membrane module. To achieve the...
|
|
WO/2023/076713A1 |
Provided herein are methods of treating a thrombotic microangiopathy (TMA) in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that binds to and inhibits MBL2 and an antibody that binds...
|
|
WO/2023/069529A1 |
In one aspect, the disclosure relates to pharmaceutical compositions comprising 2'-deoxycytidine analogs, oral and other dosage formulations containing the same, and methods of making the same. In another aspect, the disclosure relates t...
|
|
WO/2023/067620A1 |
The present invention relates to an orally disintegrating pharmaceutical compositions of Rivaroxaban or a pharmaceutically acceptable salt thereof. The present invention specifically relates to a stable orally disintegrating pharmaceutic...
|
|
WO/2023/067167A1 |
The invention relates to thrombin derived peptides comprising at least one internal covalent linkage between the side chains of two non-neighbouring, internal amino acids. The peptides have anti-inflammatory effect.
|
|
WO/2023/068700A1 |
The present invention relates to a pharmaceutical composition for preventing or treating thrombosis, comprising durumamide A. If a pharmaceutical composition comprising durumamide A as an active ingredient, according to one embodiment, i...
|
|
WO/2023/064886A1 |
The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the...
|
|
WO/2023/064255A2 |
The present invention resides in the discovery that the presence of anti-PF4 antibody in the PF4-integrin complex promotes platelet aggregation and subsequently thrombocytopenia. PF4 mutants incapable of binding integrin are also disclos...
|
|
WO/2023/060319A1 |
Disclosed are proteinaceous coagulation factor XIIa (FXIIa) inhibitors and their use for treating or inhibiting the development of a condition in which inhibiting FXIIa stimulates or effects treatment or inhibition of the development of ...
|
|
WO/2023/062092A1 |
The food additive lauryl gallate (LG, E312) is a molecule with antioxidant and hydrophobic properties which has also been shown to exert antibacterial, antiviral and anti-tumoral effects. Here, the inventors show that LG at a low concent...
|
|
WO/2023/061468A1 |
Provided are a new crystal form and use of a nitrogenous tricyclic compound in the field of drugs. Specifically, the present invention relates to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho
xy)-10H-...
|
|
WO/2023/061473A1 |
Disclosed is a new crystal form of compound 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-yl)metho
xy)-10H-spiro[benzo[6],7]oxazepine[3,2-b]pyridine-11,1'-cycl
opropane]-7-formic acid. The new crystal form is crystal form J. Furthe...
|
|
WO/2023/063306A1 |
The purpose of the present invention is to provide a granulated material for a hemodialysis agent that contains an acetic acid salt and magnesium chloride and/or calcium chloride and has excellent storage stability. A granulated materi...
|
|
WO/2023/064522A1 |
A sample collection container configured to be removably mounted to a blood collection device includes: a housing having a flow channel extending through the housing having an inlet and an outlet and a container body removably connected ...
|
